News & Updates
Filter by Specialty:
Add-on baxdrostat shows promise for hard-to-control BP
In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant hypertension (HTN).
Add-on baxdrostat shows promise for hard-to-control BP
22 Sep 2025
Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect
A low-dose combination therapy, AD-209, that includes telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg demonstrates efficacy in lowering high blood pressure (BP) when compared with telmisartan alone in patients with essential hypertension, reports a study presented at ESC 2025.
Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect
20 Sep 2025
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.